ArticlePharmaceutics2024

Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban.

Daniel Zakowiecki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.